Enliven Therapeutics (ELVN) Depreciation & Amortization (CF) (2019 - 2026)
Enliven Therapeutics (ELVN) reported Depreciation & Amortization (CF) of $14000.0 for Q1 2026, down 81.08% on a YoY basis from $74000.0 in Q1 2025, and down 83.13% sequentially from $83000.0 in Q4 2025.
Enliven Therapeutics (ELVN) Depreciation & Amortization (CF) (2019 - 2026) Analysis & Trends
Enliven Therapeutics (ELVN) has 8 years of Depreciation & Amortization (CF) data on file, last reported at $14000.0 in Q1 2026.
- For the quarter ending Q1 2026, Depreciation & Amortization (CF) fell 81.08% year-over-year to $14000.0; the trailing twelve-month figure through Mar 2026 stood at $240000.0 (down 18.92% YoY), and the FY2025 full-year result was $300000.0, changed 0.0% from the prior year.
- Depreciation & Amortization (CF) eased to $14000.0 in Q1 2026, from $83000.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $39.0 million in Q1 2022 to a low of $14000.0 in Q1 2026.
- A 5-year average of $2.4 million and a median of $74000.0 in 2023 frame the typical range for Depreciation & Amortization (CF).
- Across the five-year window, Depreciation & Amortization (CF) soared 155900.0% in 2022 and plunged 99.83% in 2023, its largest moves.
- Tracing ELVN's Depreciation & Amortization (CF) over 5 years: stood at $49000.0 in 2022, then surged by 63.27% to $80000.0 in 2023, then declined by 21.25% to $63000.0 in 2024, then surged by 31.75% to $83000.0 in 2025, then tumbled by 83.13% to $14000.0 in 2026.
- Business Quant data shows ELVN's Depreciation & Amortization (CF) at $14000.0 in Q1 2026, $83000.0 in Q4 2025, and $62000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 41.14 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 91,781.47 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.20 Mn |
| 10 | Enliven Therapeutics | 3.22 Bn | 3.22 Bn | - | 14,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14,000.00 |
| Mar 31, 2026 | 14,000.00 |
| Dec 31, 2025 | 83,000.00 |
| Dec 31, 2025 | 83,000.00 |
| Sep 30, 2025 | 62,000.00 |
| Sep 30, 2025 | 62,000.00 |
| Jun 30, 2025 | 81,000.00 |
| Jun 30, 2025 | 81,000.00 |
| Mar 31, 2025 | 74,000.00 |
| Mar 31, 2025 | 74,000.00 |
| Dec 31, 2024 | 63,000.00 |
| Dec 31, 2024 | 63,000.00 |
| Sep 30, 2024 | 80,000.00 |
| Sep 30, 2024 | 80,000.00 |
| Jun 30, 2024 | 79,000.00 |
| Jun 30, 2024 | 79,000.00 |
| Mar 31, 2024 | 79,000.00 |
| Mar 31, 2024 | 79,000.00 |
| Dec 31, 2023 | 80,000.00 |
| Dec 31, 2023 | 80,000.00 |